# Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT00186875** · PHASE2 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 47 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoma, Lymphoblastic

## Interventions

- **DRUG:** Etoposide, cytarabine, vincristine, dexamethasone
- **DRUG:** methotrexate, teniposide, PEG-asparaginase
- **DRUG:** mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
- **DRUG:** L-asparaginase, erwinia asparaginase
- **PROCEDURE:** chemotherapy, intrathecal chemotherapy, steroid therapy
- **PROCEDURE:** Hematopoietic Stem Cell Transplant
- **PROCEDURE:** Natural Killer (NK) Cell Transplant

## Key facts

- **NCT ID:** NCT00186875
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00186875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00186875, "Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00186875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*